CO6450654A2 - Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas - Google Patents

Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas

Info

Publication number
CO6450654A2
CO6450654A2 CO11141472A CO11141472A CO6450654A2 CO 6450654 A2 CO6450654 A2 CO 6450654A2 CO 11141472 A CO11141472 A CO 11141472A CO 11141472 A CO11141472 A CO 11141472A CO 6450654 A2 CO6450654 A2 CO 6450654A2
Authority
CO
Colombia
Prior art keywords
subjects
identification
neurodegenerative diseases
antibodies
small molecules
Prior art date
Application number
CO11141472A
Other languages
English (en)
Inventor
Reddy Moola
Dwight German
Steven Connell
Rosemary Wilson
Johnnie Wilson
Thomas Kodadek
Original Assignee
Regenst Of The University Of Texas System Board Of
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269525&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6450654(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenst Of The University Of Texas System Board Of, Opko Health Inc filed Critical Regenst Of The University Of Texas System Board Of
Publication of CO6450654A2 publication Critical patent/CO6450654A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se proporciona para la identificación de individuos que tienen enfermedades neurodegenerativas (ND). Los peptoides reconocidos por anticuerpos específicos de la enfermedad de Parkinson- y Enfermedad de Alzheimer se identifican, permitiendo diagnosticar o predecir ND en sujetos.
CO11141472A 2009-06-02 2011-10-21 Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas CO6450654A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18326009P 2009-06-02 2009-06-02
US31865510P 2010-03-29 2010-03-29

Publications (1)

Publication Number Publication Date
CO6450654A2 true CO6450654A2 (es) 2012-05-31

Family

ID=42269525

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11141472A CO6450654A2 (es) 2009-06-02 2011-10-21 Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas

Country Status (16)

Country Link
US (1) US9551721B2 (es)
EP (1) EP2438444A1 (es)
JP (1) JP5828837B2 (es)
KR (1) KR20120122869A (es)
CN (1) CN102439451B (es)
AU (1) AU2010256880B2 (es)
BR (1) BRPI1013012A2 (es)
CA (1) CA2764153C (es)
CL (1) CL2011002973A1 (es)
CO (1) CO6450654A2 (es)
HK (1) HK1169709A1 (es)
IL (1) IL216689A (es)
MX (1) MX2011012933A (es)
RU (1) RU2566064C2 (es)
TW (1) TWI569014B (es)
WO (1) WO2010141421A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096893A2 (en) 2011-01-10 2012-07-19 Opko Pharmaceuticals, Llc Antigen surrogates in autoimmune disease
EP2688911B1 (en) 2011-03-24 2017-08-02 OPKO Pharmaceuticals, LLC Biomarker discovery in complex biological fluid using bead or particle based libraries
EP2705180A4 (en) * 2011-05-06 2015-04-22 Elwha Llc COMPOSITIONS AND METHODS FOR IDENTIFICATION OF ANTIBODY AND LIGAND
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
EP3370518B1 (en) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
CN109153702B (zh) * 2016-03-09 2022-05-17 迈克·安有限责任公司 类肽亲和配体
WO2017165438A1 (en) 2016-03-25 2017-09-28 Muralidhar Reddy Moola Combinatorial synthesis and biomarker development
CN106866794B (zh) * 2017-02-15 2020-09-08 国家纳米科学中心 一种类肽及其制备方法和应用
CN108484905A (zh) * 2018-04-16 2018-09-04 青岛科技大学 一种侧链含羧基具有ucst行为的聚类肽及其制备方法
WO2019211878A1 (en) * 2018-05-04 2019-11-07 Council Of Scientific And Industrial Research, An Indian Registered Body Incorporated Under The Registration Of Societies Act (Act Xxi Of 1860) Peptoid of formula i, pharmaceutical compositions and method for preparation thereof
CN108586579B (zh) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 一种类肽及其衍生物、盐、制备方法和用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4789628A (en) * 1986-06-16 1988-12-06 Vxr, Inc. Devices for carrying out ligand/anti-ligand assays, methods of using such devices and diagnostic reagents and kits incorporating such devices
CA1304682C (en) 1986-11-19 1992-07-07 Nobuo Monji Membrane affinity concentration immunoassay
US5149626A (en) * 1987-05-14 1992-09-22 Mclean Hospital Corporation Multiple antigen immunoassay
EP0317804B1 (en) 1987-11-24 1995-10-04 Abbott Laboratories HIV peptides and methods for detection of HIV
DE4040669A1 (de) 1990-12-19 1992-06-25 Behringwerke Ag Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
CA2115333A1 (en) * 1993-02-16 1994-08-17 Shigeo Hozumi Polyfunctional vinyl ether compounds and photoresist resin composition containing the same
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
ES2201077T3 (es) * 1993-05-28 2004-03-16 Baylor College Of Medicine Metodo y espectrometro de masas para la desorcion e ionizacion de analitos.
ZA95605B (en) * 1994-04-28 1995-12-20 Qualcomm Inc Method and apparatus for automatic gain control and dc offset cancellation in quadrature receiver
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
BR9608587A (pt) * 1995-06-07 1999-01-05 Glaxo Group Ltd Composto que se liga ao receptor de trombopoietina composição farmacêutica e processo para o tratamento de um paciente sofrendo de um distúrbio
JPH1025299A (ja) 1996-07-12 1998-01-27 Nec Corp 整列ペプチド、及びそれを用いたタンパク質の結合・相互作用部位検出方法
US20020006620A1 (en) * 1996-10-17 2002-01-17 Invitrogen Corporation Morphatides: novel shape and structure libraries
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US6153596A (en) * 1996-12-18 2000-11-28 Emory University Polycationic oligomers
US6365347B1 (en) * 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406632B1 (en) * 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
US6297059B1 (en) * 1998-06-22 2001-10-02 The Regents Of The University Of California Triggered optical biosensor
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6306643B1 (en) * 1998-08-24 2001-10-23 Affymetrix, Inc. Methods of using an array of pooled probes in genetic analysis
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US6465183B2 (en) * 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
AU1630501A (en) * 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
AU1452701A (en) * 1999-11-02 2001-05-14 Chiron Corporation Biological sample component purification and differential display
WO2001057530A1 (en) 2000-02-03 2001-08-09 Immunomatrix Inc. Method and apparatus for signal transduction pathway profiling
KR20020081330A (ko) 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
DE60121923T2 (de) 2000-03-16 2006-11-30 Biacore Ab Verfahren zur erfassung von analyten, die aus oberflächengebundenen liganden eluiert werden
CA2723664A1 (en) * 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
JP2004511753A (ja) * 2000-05-04 2004-04-15 イエール　ユニバーシティー タンパク質活性のスクリーニング用タンパク質チップ
EP1314032A2 (en) 2000-05-12 2003-05-28 David P. Dumas Compositions and methods for epitope mapping
US20020108130A1 (en) * 2000-05-25 2002-08-08 Asher Nathan Extracellular drug-oligonucleotides chimeric molecules
US7153682B2 (en) * 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US20020055125A1 (en) * 2000-06-05 2002-05-09 Chiron Corporation Microarrays for performing proteomic analyses
US7148058B2 (en) 2000-06-05 2006-12-12 Chiron Corporation Protein microarrays on mirrored surfaces for performing proteomic analyses
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
EP1292710B1 (en) 2000-06-23 2007-08-29 Domantis Limited Matrix screening method
CA2419490C (en) * 2000-08-15 2010-01-26 Discerna Limited Functional protein arrays
WO2002018648A2 (en) 2000-08-25 2002-03-07 President And Fellows Of Harvard College Analysis of binding interactions
GB0022978D0 (en) * 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
CA2432639A1 (en) * 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US20020137104A1 (en) 2000-11-27 2002-09-26 Antonio Cosma High throughput determination of antigen expression
EP1343914A2 (en) * 2000-12-11 2003-09-17 HK Pharmaceuticals, Inc. Multiplexed protein expression and activity assay
WO2002059601A1 (en) * 2001-01-23 2002-08-01 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
JP2004531700A (ja) 2001-02-05 2004-10-14 グラフィニティー、ファーマスーティカルス アーゲー 低親和性スクリーニング法
US20020137106A1 (en) * 2001-03-09 2002-09-26 Ciphergen Biosystems, Inc. Detection of biological pathway components
WO2002073209A2 (de) 2001-03-10 2002-09-19 Affina Immuntechnik Gmbh Verfahren zur identifikation von immunreaktiven epitopen auf proteinen
CA2443777A1 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
US6777239B2 (en) * 2001-04-17 2004-08-17 Xenoport, Inc. Epitope-captured antibody display
WO2002085926A2 (de) * 2001-04-19 2002-10-31 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US6989276B2 (en) * 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
WO2003019192A1 (en) * 2001-08-27 2003-03-06 The Trustees Of Boston University Apparatus, composition and method for proteome profiling
AU2002367732A1 (en) 2001-10-31 2003-09-09 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
EP1319954A1 (en) 2001-12-12 2003-06-18 Centre National de Genotypage Methods for protein analysis using protein capture arrays
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
CA2478298A1 (en) 2002-03-07 2003-09-12 Zephyr Proteomix Ltd. Microarrays of cellulose binding chimeric proteins and methods of use thereof
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
US7794947B2 (en) 2003-07-10 2010-09-14 Institute For Systems Biology Affinity capture of peptides by microarray and related methods
GB2404734A (en) 2003-08-05 2005-02-09 Secr Defence A method of screening a sample for abnormally glycosylated and/or expressed proteins
US7504365B2 (en) * 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
JP5209477B2 (ja) 2005-09-09 2013-06-12 ノバルティス アーゲー プリオンに特異的なペプトイド試薬
CA2666507A1 (en) 2006-10-16 2008-04-24 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University Synthetic antibodies
US20100303835A1 (en) 2009-05-29 2010-12-02 The Board Of Regents Of The University Of Texas System Peptoid ligands for isolation and treatment of autoimmune t-cells

Also Published As

Publication number Publication date
MX2011012933A (es) 2012-03-07
CA2764153C (en) 2021-07-27
AU2010256880A1 (en) 2011-11-03
HK1169709A1 (en) 2013-02-01
TW201109662A (en) 2011-03-16
KR20120122869A (ko) 2012-11-07
AU2010256880B2 (en) 2015-01-22
IL216689A0 (en) 2012-02-29
US9551721B2 (en) 2017-01-24
CN102439451A (zh) 2012-05-02
CA2764153A1 (en) 2010-12-09
WO2010141421A1 (en) 2010-12-09
TWI569014B (zh) 2017-02-01
IL216689A (en) 2016-09-29
JP5828837B2 (ja) 2015-12-09
CN102439451B (zh) 2014-12-03
RU2566064C2 (ru) 2015-10-20
JP2012529053A (ja) 2012-11-15
BRPI1013012A2 (pt) 2016-10-18
US20100303805A1 (en) 2010-12-02
CL2011002973A1 (es) 2012-03-23
EP2438444A1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
CO6450654A2 (es) Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas
ECSP13012609A (es) Composición farmacéutica
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
ECSP11011367A (es) Composición farmacéutica
AR092818A1 (es) Anticuerpo tau humanizado
BR112017010498A2 (pt) anticorpos tau humanizados em doença de alzheimer
GT201200109A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112013004581A2 (pt) imunoglobulinas de domínio variável dual e seus usos
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CR20150016A (es) Anticuerpo monoclonal
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
BR112012032389A2 (pt) biomarcadores para a previsão de câncer incidente
BR112014029219A8 (pt) moléculas de ligação de il-6
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar
BR112015027249A2 (pt) método de diagnóstico de câncer
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher

Legal Events

Date Code Title Description
FC Application refused